SG11202007120UA - Methyllactam ring compound and pharmaceutical use thereof - Google Patents

Methyllactam ring compound and pharmaceutical use thereof

Info

Publication number
SG11202007120UA
SG11202007120UA SG11202007120UA SG11202007120UA SG11202007120UA SG 11202007120U A SG11202007120U A SG 11202007120UA SG 11202007120U A SG11202007120U A SG 11202007120UA SG 11202007120U A SG11202007120U A SG 11202007120UA SG 11202007120U A SG11202007120U A SG 11202007120UA
Authority
SG
Singapore
Prior art keywords
methyllactam
pharmaceutical use
ring compound
pharmaceutical
compound
Prior art date
Application number
SG11202007120UA
Other languages
English (en)
Inventor
Tomoya Miura
Yoshinori Tamatani
Original Assignee
Japan Tobacco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan Tobacco Inc filed Critical Japan Tobacco Inc
Publication of SG11202007120UA publication Critical patent/SG11202007120UA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
SG11202007120UA 2018-03-01 2019-02-28 Methyllactam ring compound and pharmaceutical use thereof SG11202007120UA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2018036307 2018-03-01
PCT/JP2019/007799 WO2019168096A1 (ja) 2018-03-01 2019-02-28 メチルラクタム環化合物及びその医薬用途

Publications (1)

Publication Number Publication Date
SG11202007120UA true SG11202007120UA (en) 2020-08-28

Family

ID=67806229

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202007120UA SG11202007120UA (en) 2018-03-01 2019-02-28 Methyllactam ring compound and pharmaceutical use thereof

Country Status (21)

Country Link
US (4) US11014910B2 (cg-RX-API-DMAC7.html)
EP (1) EP3760624A4 (cg-RX-API-DMAC7.html)
JP (3) JP7206132B2 (cg-RX-API-DMAC7.html)
KR (1) KR102795351B1 (cg-RX-API-DMAC7.html)
CN (1) CN111757877B (cg-RX-API-DMAC7.html)
AR (1) AR114418A1 (cg-RX-API-DMAC7.html)
AU (1) AU2019227770B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020016788A2 (cg-RX-API-DMAC7.html)
CA (1) CA3087859A1 (cg-RX-API-DMAC7.html)
CL (1) CL2020002199A1 (cg-RX-API-DMAC7.html)
IL (1) IL276311B2 (cg-RX-API-DMAC7.html)
MA (1) MA52427A (cg-RX-API-DMAC7.html)
MX (1) MX2020009070A (cg-RX-API-DMAC7.html)
MY (1) MY205197A (cg-RX-API-DMAC7.html)
PE (1) PE20210123A1 (cg-RX-API-DMAC7.html)
PH (1) PH12020551340A1 (cg-RX-API-DMAC7.html)
SA (1) SA520420037B1 (cg-RX-API-DMAC7.html)
SG (1) SG11202007120UA (cg-RX-API-DMAC7.html)
TW (1) TWI805699B (cg-RX-API-DMAC7.html)
WO (1) WO2019168096A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202004600B (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI805699B (zh) * 2018-03-01 2023-06-21 日商日本煙草產業股份有限公司 甲基內醯胺環化合物及其用途
TWI805727B (zh) 2018-04-04 2023-06-21 日商日本煙草產業股份有限公司 經雜芳基取代之吡唑化合物及其醫藥用途
CN114585387B (zh) * 2019-09-04 2024-10-29 日本烟草产业株式会社 利用联用药物的糖尿病的治疗或预防方法
CN114641314B (zh) * 2019-09-04 2024-05-28 日本烟草产业株式会社 慢性肾脏病的治疗或预防方法
EP4122495A4 (en) * 2020-03-19 2024-03-27 Japan Tobacco Inc. Treatment or prevention method for chronic heart failure

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3657282A (en) * 1969-01-23 1972-04-18 Merck & Co Inc Carboxyepoxyethyl-1-phosphonic acid and derivatives
FR2665898B1 (fr) 1990-08-20 1994-03-11 Sanofi Derives d'amido-3 pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
JPH04247081A (ja) 1991-02-01 1992-09-03 Takeda Chem Ind Ltd 5員複素環酸アミド類
FR2692575B1 (fr) 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
RU2332412C2 (ru) 2003-02-07 2008-08-27 Дайити Фармасьютикал Ко., Лтд. Производные пиразола
AU2004200420A1 (en) 2003-03-11 2004-09-30 Astellas Pharma Inc. Inhibitor of cyclooxygenase
JP2006182648A (ja) 2003-04-08 2006-07-13 Dai Ichi Seiyaku Co Ltd 7員複素環誘導体
US20050075375A1 (en) 2003-05-14 2005-04-07 Anadys Pharmaceuticals, Inc. Heterocyclic compounds for treating hepatitis C virus
TW200526588A (en) 2003-11-17 2005-08-16 Smithkline Beecham Corp Chemical compounds
TW200526641A (en) 2003-12-26 2005-08-16 Daiichi Seiyaku Co Amidopyrazole derivatives
DE602005017895D1 (de) 2004-07-07 2010-01-07 Merck & Co Inc Pyrazolamid-derivate, diese verbindungen enthaltende zusammensetzungen und anwendungsverfahren
US9168278B2 (en) 2004-11-16 2015-10-27 Gw Pharma Limited Use for cannabinoid
JP2008007405A (ja) 2004-12-07 2008-01-17 Takeda Chem Ind Ltd カルボキサミド誘導体
JP4137956B2 (ja) * 2005-06-08 2008-08-20 日本たばこ産業株式会社 複素環化合物
KR100970294B1 (ko) 2005-06-08 2010-07-15 니뽄 다바코 산교 가부시키가이샤 복소환 화합물
CN101243074A (zh) * 2005-06-08 2008-08-13 日本烟草产业株式会社 杂环化合物
WO2007034279A2 (en) 2005-09-19 2007-03-29 Pfizer Products Inc. C3a antagonists and pharmaceutical compositions thereof
EP1991528A2 (en) 2006-01-18 2008-11-19 Siena Biotech S.p.A. Modulators of alpha7 nicotinic acetylcholine receptors and therapeutic uses thereof
CA2650566A1 (en) * 2006-04-27 2007-11-08 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising cbx cannabinoid receptor modulators and potassium channel modulators
US20080027014A1 (en) 2006-07-28 2008-01-31 Tanabe Seiyaku Co., Ltd. Novel SGLT inhibitors
SG173409A1 (en) 2006-11-24 2011-08-29 Ac Immune Sa N-(methyl)-1h-pyrazol-3-amine, n-(methyl)-pyridin-2-amine and n-(methyl)-thiazol-2-amine derivatives for the treatment of diseases associated with amyloid or amyloid-like proteins, like e.g. alzheimers
EP2121619A2 (en) 2006-11-24 2009-11-25 AC Immune S.A. Compounds for the treatment of diseases associated with amyloid or amyloid-like proteins
TW200901974A (en) 2007-01-16 2009-01-16 Wyeth Corp Compounds, compositions, and methods of making and using them
EP2064222B1 (en) * 2007-04-02 2014-05-07 Theracos, Inc. Benzylic glycoside derivatives and methods of use
WO2009091813A1 (en) 2008-01-14 2009-07-23 Wyeth Compounds useful as alpha7 nicotinic acetylcholine receptor agonists
EP2349484A2 (en) 2008-07-15 2011-08-03 Novartis AG Heteroaryl derivatives as dgat1 inhibitors
SG10201502484SA (en) 2010-03-30 2015-05-28 Verseon Corp Multisubstituted aromatic compounds as inhibitors of thrombin
AR087701A1 (es) 2011-08-31 2014-04-09 Japan Tobacco Inc Derivados de pirazol con actividad inhibidora de sglt1
JP6929792B2 (ja) * 2015-02-16 2021-09-01 ザ ユニバーシティ オブ クィーンズランド スルホニル尿素及び関連化合物並びにその使用
BR112018016671A2 (pt) * 2016-02-16 2018-12-26 The University Of Queensland sulfonilureias e compostos relacionados e uso do mesmo
TWI805699B (zh) * 2018-03-01 2023-06-21 日商日本煙草產業股份有限公司 甲基內醯胺環化合物及其用途
TWI805727B (zh) 2018-04-04 2023-06-21 日商日本煙草產業股份有限公司 經雜芳基取代之吡唑化合物及其醫藥用途

Also Published As

Publication number Publication date
MX2020009070A (es) 2020-10-08
SA520420037B1 (ar) 2024-07-28
US20220064148A1 (en) 2022-03-03
CA3087859A1 (en) 2019-09-06
US20240174646A1 (en) 2024-05-30
TW202000660A (zh) 2020-01-01
CN111757877A (zh) 2020-10-09
MA52427A (fr) 2021-01-06
IL276311A (en) 2020-09-30
BR112020016788A2 (pt) 2021-01-12
JP2025026615A (ja) 2025-02-21
RU2020131756A (ru) 2022-03-28
CN111757877B (zh) 2023-10-27
CL2020002199A1 (es) 2020-12-18
MY205197A (en) 2024-10-07
AU2019227770A1 (en) 2020-07-09
KR102795351B1 (ko) 2025-04-16
AR114418A1 (es) 2020-09-02
JP2023026566A (ja) 2023-02-24
PH12020551340A1 (en) 2021-05-31
WO2019168096A1 (ja) 2019-09-06
US20190352284A1 (en) 2019-11-21
AU2019227770B2 (en) 2023-10-05
ZA202004600B (en) 2022-03-30
US20260152490A1 (en) 2026-06-04
JP2019151627A (ja) 2019-09-12
IL276311B2 (en) 2023-10-01
IL276311B1 (en) 2023-06-01
EP3760624A4 (en) 2021-11-03
EP3760624A1 (en) 2021-01-06
US11014910B2 (en) 2021-05-25
PE20210123A1 (es) 2021-01-19
KR20200128033A (ko) 2020-11-11
TWI805699B (zh) 2023-06-21
JP7206132B2 (ja) 2023-01-17

Similar Documents

Publication Publication Date Title
GB2572126B (en) Pharmaceutical
GB2569961B (en) Pharmaceutical
GB2572125B (en) Pharmaceutical
SI3565550T1 (sl) Farmacevtske sestave, ki vsebujejo meloksikam in rizatriptan
IL290745A (en) A pyrimidine compound and its pharmaceutical use
IL276311A (en) Methyllactam ring compound and its pharmaceutical use
IL273339A (en) Griseofulbin compound and its medical use
IL272385A (en) Drug compound and methods of preparation
IL277749A (en) Palladianolide compounds and their use
IL276323A (en) 4-Methyldihydropyrimidinone compounds and their pharmaceutical use
IL276912A (en) Heterocyclic compound and its use
IL280644A (en) Magnesium-serinate compound and use thereof
ZA202008034B (en) Ivosidenib forms and pharmaceutical compositions
ZA202006347B (en) Anti-inflammatory compound and preparation and use thereof
IL276783A (en) The composition and pharmaceutical compound containing it
SG11202104371XA (en) 1,3,4-oxadiazolone compound and pharmaceutical
SG11202103011YA (en) Aromatic compounds and pharmaceutical uses thereof
HUE061891T2 (hu) 4-pirazin-2-ilmetil-morfolin származékok és azok gyógyszerként történõ alkalmazása
IL292646A (en) Pharmaceutical combination and its use
IL283540A (en) Dock1 inhibitory compound and use thereof
GB201917327D0 (en) New pharmaceutical use
GB201814520D0 (en) New pharmaceutical use
GB201913328D0 (en) New Pharmaceutical use
GB201802743D0 (en) Medicament and use thereof
HK40039345A (en) New pharmaceutical use